Nothing said here yet.
to join the conversation.
| SCHMERTZLER MICHAELDirector | Sell | 2,118 | $126.1K | Wed, Oct 14 |
| SCHMERTZLER MICHAELDirector | Sell | 382 | $23.0K | Wed, Oct 14 |
| Boulding Mark ElliottEXEC. VP AND CLO | Sell | 192 | $12.3K | Fri, Oct 9 |
| SCHMERTZLER MICHAELDirector | Sell | 2,447 | $155.1K | Wed, Oct 7 |
| SCHMERTZLER MICHAELDirector | Sell | 53 | $3.4K | Wed, Oct 7 |
| Boulding Mark ElliottEXEC. VP AND CLO | Sell | 435 | $27.9K | Tue, Oct 6 |
| Boulding Mark ElliottEXEC. VP AND CLO | Sell | 1,638 | $104.9K | Mon, Oct 5 |
| STEELE GLENN JR MD PHDDirector | Sell | 12,000 | $781.9K | Wed, Sep 30 |
| SCHMERTZLER MICHAELDirector | Sell | 9,624 | $652.8K | Thu, Sep 17 |
| SCHMERTZLER MICHAELDirector | Sell | 376 | $25.7K | Thu, Sep 17 |
| SCHMERTZLER MICHAELDirector | Sell | 7,006 | $471.9K | Wed, Sep 16 |
| SCHMERTZLER MICHAELDirector | Sell | 2,994 | $199.3K | Wed, Sep 16 |
PTC Therapeutics just reported Q3 2026 and the headline is simple. Product revenue is now anchored by Sephience and Q3 brought in US$358 million of total revenue, yet the stock dropped about 7% on the day to roughly US$60. That is the sentiment shock.
PTC Therapeutics (PTCT) is back in focus after its third quarter, when revenue of US$357.81 million topped analyst forecasts and management lifted full year sales guidance for 2026.
PTC Therapeutics (NASDAQ:PTCT) reported third-quarter 2026 total revenue of $358 million, including $276 million in net product revenue, as sales of phenylketonuria treatment Sephience continued to expand in the United States and internationally.
The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of +258.82% and +15.02%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
(PTCT) on Thursday reported a loss of $51.The Warren, New Jersey-based company said it had a loss of 62 cents per share.
PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WARREN, N.J., Sept. 25, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Sept.
PTC Therapeutics (PTCT) heads into its next earnings report with consensus EPS forecasts unchanged over the past month, even as the stock ticked 0.6% higher in the last session to close at $68.